Skip to content
OpenCapital
Get started

BillionToOne, Inc. BLLN Oncology — Revenue

Other product segments

Prenatal
$96.53M+72.1%
Clinical trial support and other services
$1.14M+61.0%

Similar metrics at other companies

Guardant Health logo
GHOncology — Total Revenue
$204.95M+36.1%
Natera, Inc. logo
NTRAOncology — Revenue recognized
$100K0.0%
Eli Lilly logo
LLYOncology — Revenue
$2.27B+16.4%
Jazz Pharmaceuticals logo
JAZZOncology — Revenue from Contract with Customer, Excluding Assessed Tax
$333.4M+45.3%
Lantheus Holdings logo
LNTHOncology — Revenue
$240.92M-6.5%
Medpace Holdings, Inc. logo
MEDPOncology — Total Revenue
$237.56M+60.5%

Other financials

Income statement

See full
Revenue$108.4M+83.8%
Gross profit$79.1M+108%
Operating income$17.8M+870%
Net income$18.0M+551%
EPS (diluted)$0.34+187%

Balance sheet

See full
Cash & equivalents$537.5M+181%
Total debt$144.2M—
Total equity$505.6M+300%
Total assets$700.7M—

Cash flow

See full
Operating cash flow$15.4M+488%
CapEx$4.5M+90.5%
Free cash flow$11.0M+3,842%

Valuation

See full
Market cap$4.84B—
Enterprise value$4.44B—
P/E163.1×—
P/S13.6×—

Profitability

See full
Gross margin70.4%—
Operating margin-96.9%—
Net margin8.4%—
FCF margin-83.4%—

Returns & leverage

See full
Return on equity23.5%—
Debt / equity0.3×—
Current ratio10.9×—

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: BillionToOne, Inc. ’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's oncology — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BillionToOne, Inc. 's oncology — revenue?
BillionToOne, Inc. (BLLN) reported oncology — revenue of $10.72M in Q1 2026.
How has BillionToOne, Inc. 's oncology — revenue changed year-over-year?
BillionToOne, Inc. 's oncology — revenue increased by 392.4% year-over-year, from $2.18M to $10.72M.
What does oncology — revenue mean?
This metric represents the total gross income generated from the sale of oncology-focused molecular diagnostic products and liquid biopsy testing services. It serves as a primary indicator of the company's market penetration and commercial adoption within the cancer diagnostics sector. Growth in this segment reflects the successful scaling of specialized clinical testing solutions and the expansion of the company's precision oncology portfolio.